KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Ginkgo Bioworks Holdings (DNA) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity fell 19.70% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 billion, marking a year-over-year decrease of 19.87%. This contributed to the annual value of $1.4 billion for FY2024, which is 17.29% down from last year.
  • As of Q3 2025, Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity stood at $1.2 billion, which was down 3.40% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity peaked at $2.5 billion during Q4 2022, and registered a low of $1.2 billion during Q3 2025.
  • Over the past 3 years, Ginkgo Bioworks Holdings' median Liabilities and Shareholders Equity value was $1.6 billion (recorded in 2024), while the average stood at $1.7 billion.
  • Per our database at Business Quant, Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity soared by 206.74% in 2021 and then slumped by 34.56% in 2024.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $2.1 billion in 2021, then increased by 22.61% to $2.5 billion in 2022, then slumped by 34.42% to $1.7 billion in 2023, then decreased by 17.29% to $1.4 billion in 2024, then dropped by 19.70% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.